Physician profile
Arthur Silverstein
NPI 1376549220
$3,762.84
in general payments reported to CMS, 2019-2025
9 companies · $14.06 in 2025
The $14.06 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $734 · 2021: $793 · 2022: $804 · 2023: $319 · 2024: $192 · 2025: $14.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,719.26 | 2019-2024 | Assurity, Gallant, Jot Dx |
| Janssen Pharmaceuticals, INC | $613.25 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $182.88 | 2019-2024 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $57.18 | 2022-2023 | Farxiga |
| Philips North America LLC | $51.01 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Medtronic Vascular, INC. | $50.21 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $32.90 | 2021 | |
| Amgen INC. | $30.71 | 2023 | Repatha |
| Daiichi Sankyo INC. | $25.44 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Silverstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.